Robert-Jan Van Son

Robert-Jan Van Son


Robert-Jan is a results-driven biotech leader with deep expertise in supporting biotech companies by creating (early) market access for innovative drugs launching in Europe, especially in the Nordic and Benelux countries.

With over twenty-five years of experience, he has been in various management positions with increasing responsibilities in sales, marketing, market access, operations, project leadership, and regional management.

Before becoming a consultant, Robert-Jan worked for companies such as AstraZeneca, Schering-Plough (MSD), and Celgene. At Celgene, he built the Dutch organization from scratch and re-structured the Nordic organization into a healthy, well-managed team. He then became regional general manager, heading the Nordic and Benelux organization, while leading a very successful European launch of Imnovid® (pomalidomide), as well.

Robert-Jan also served as COO at MyTomorrows, an Internet platform supporting patients with high unmet medical needs. In this role, he helped build a successful start-up organization, optimized the business model, restructured the organization, and hired key talent. During his tenure, MyTomorrows gained its manufacturing and wholesaler license for early access treatment (Phase II+ products).

A highly accomplished and results-driven executive, Robert-Jan’s experience is both cross-cultural and cross-functional. He is innovative, and he takes ownership and creates structure where needed. A passionate leader, Robert-Jan’s leadership style fosters mutual trust and respect while encouraging both personal accomplishments and successful teamwork.

Robert-Jan has a medical degree from Utrecht University, and he also trained at Cranfield School of Management at Cranfield University. Most of his experience is in early access oncology, CNS, and (ultra-) rare diseases. He deeply believes that patients should always be put first!